Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Mark M. Smits; Lennart Tonneijck; Marcel H. A. Muskiet; Mark H. H. Kramer; Petra J. W. Pouwels; Indra C. Pieters-van den Bos; Trynke Hoekstra; Michaela Diamant; Daniel H. van Raalte; Djuna L. Cahen

doi:10.1007/s00125-016-4100-7

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

Mark M. Smits, Lennart Tonneijck, Marcel H. A. Muskiet, Mark H. H. Kramer, Petra J. W. Pouwels, Indra C. Pieters-van den Bos, Trynke Hoekstra, Michaela Diamant, Daniel H. van Raalte, Djuna L. Cahen

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	2588-2593
Journal	Diabetologia
Volume	59
Issue number	12
DOIs	https://doi.org/10.1007/s00125-016-4100-7
Publication status	Published - Dec 2016

Cite this

Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Pouwels, P. J. W., Pieters-van den Bos, I. C., ... Cahen, D. L. (2016). Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. Diabetologia, 59(12), 2588-2593. https://doi.org/10.1007/s00125-016-4100-7

Smits, Mark M. ; Tonneijck, Lennart ; Muskiet, Marcel H. A. ; Kramer, Mark H. H. ; Pouwels, Petra J. W. ; Pieters-van den Bos, Indra C. ; Hoekstra, Trynke ; Diamant, Michaela ; van Raalte, Daniel H. ; Cahen, Djuna L. / Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. In: Diabetologia. 2016 ; Vol. 59, No. 12. pp. 2588-2593.

@article{c5d7403bb4a3416f8e9d12537cfe808b,

title = "Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial",

keywords = "Dipeptidyl peptidase-4 inhibitor, Glucagon-like peptide-1 receptor agonist, Non-alcoholic fatty liver disease, Type 2 diabetes",

author = "Smits, {Mark M.} and Lennart Tonneijck and Muskiet, {Marcel H. A.} and Kramer, {Mark H. H.} and Pouwels, {Petra J. W.} and {Pieters-van den Bos}, {Indra C.} and Trynke Hoekstra and Michaela Diamant and {van Raalte}, {Daniel H.} and Cahen, {Djuna L.}",

year = "2016",

month = "12",

doi = "10.1007/s00125-016-4100-7",

language = "English",

volume = "59",

pages = "2588--2593",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Verlag",

number = "12",

}

Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. / Smits, Mark M.; Tonneijck, Lennart ; Muskiet, Marcel H. A.; Kramer, Mark H. H.; Pouwels, Petra J. W.; Pieters-van den Bos, Indra C.; Hoekstra, Trynke; Diamant, Michaela; van Raalte, Daniel H.; Cahen, Djuna L.

In: Diabetologia, Vol. 59, No. 12, 12.2016, p. 2588-2593.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial

AU - Smits, Mark M.

AU - Tonneijck, Lennart

AU - Muskiet, Marcel H. A.

AU - Kramer, Mark H. H.

AU - Pouwels, Petra J. W.

AU - Pieters-van den Bos, Indra C.

AU - Hoekstra, Trynke

AU - Diamant, Michaela

AU - van Raalte, Daniel H.

AU - Cahen, Djuna L.

PY - 2016/12

Y1 - 2016/12

KW - Dipeptidyl peptidase-4 inhibitor

KW - Glucagon-like peptide-1 receptor agonist

KW - Non-alcoholic fatty liver disease

KW - Type 2 diabetes

U2 - 10.1007/s00125-016-4100-7

DO - 10.1007/s00125-016-4100-7

M3 - Article

C2 - 27627981

VL - 59

SP - 2588

EP - 2593

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 12

ER -

Access to Document

10.1007/s00125-016-4100-7